Nature Clinical Practice. Oncology最新文献

Nature Clinical Practice. Oncology Pub Date : 2019-09-30 DOI: 10.1038/ncponc0861

Proyecto Imagine, Juegos Digitales, Para EL Aprendizaje

引用次数: 8

Modelo comparativo entre terapia inicial con un inhibidor de la aromatasa y tratamiento secuencial después de tamoxifeno 芳香化酶抑制剂初始治疗与他莫昔芬后连续治疗的比较模型

Nature Clinical Practice. Oncology Pub Date : 2007-01-01 DOI: 10.1038/NCPONC0859

Jack Cuzick

引用次数: 0

Hormonoterapia secuencial en el cáncer de mama metastásico 这是一种非常有效的治疗乳腺癌的方法。

Nature Clinical Practice. Oncology Pub Date : 2007-01-01 DOI: 10.1038/ncponc0857

R. Chacón

引用次数: 0

Inhibidores de la aromatasa en el tratamiento del cáncer de mama. Resultados del ensayo ATAC 芳香化酶抑制剂在乳腺癌治疗中的作用。hvac测试结果

Nature Clinical Practice. Oncology Pub Date : 2007-01-01 DOI: 10.1038/ncponc0858

Jack Cuzick

引用次数: 2

Fulvestrant: Un inhibidor de los receptores de estrógeno 氟维司汀:一种雌激素受体抑制剂

Nature Clinical Practice. Oncology Pub Date : 2007-01-01 DOI: 10.1038/ncponc0860

S. Simón

引用次数: 0

Inhibitors of DNA methylation: beyond myelodysplastic syndromes. DNA甲基化抑制剂:超越骨髓增生异常综合征。

Nature Clinical Practice. Oncology Pub Date : 2005-12-01 DOI: 10.1038/ncponc0351

Pierre Fenaux

{"title":"Inhibitors of DNA methylation: beyond myelodysplastic syndromes.","authors":"Pierre Fenaux","doi":"10.1038/ncponc0351","DOIUrl":"https://doi.org/10.1038/ncponc0351","url":null,"abstract":"DNA methyltransferase (DNMT) inhibitors, azacitidine (Vidaza, Pharmion, Boulder, CO, USA) and decitabine (Dacogen; SuperGen Inc, Dublin, CA, USA, and MGI Pharma Inc, Bloomington, MN, USA), have had a significant impact on the treatment paradigm of myelodysplastic syndromes (MDSs), previously managed mainly by supportive care and hematopoietic-stem-cell transplantation. The positive clinical experience seen in MDS to date coupled with the persistent challenges faced in the treatment of other hematologic malignancies has served as the impetus for further exploration of the therapeutic value of DNMT inhibitors beyond MDS. In that respect, the majority of data for these agents are in the setting of acute myelogenous leukemia (AML). Experience with these agents in patients with refractory anemia with excess blasts in transformation (reclassified by the World Health Organization as AML) was also reported in the clinical trials submitted to the FDA for approval of azacitidine for MDS. Some use has also been described in chronic myelogenous leukemia and acute lymphocytic leukemia. Further studies are needed to clarify the appropriate dose and the number and duration of cycles in the treatment of leukemias, and to identify ideal candidates for therapy, explore the role of DNMT inhibitors in combination with other agents, especially histone deacetylase inhibitors, delineate differences between the commercially available agents, and establish the long-term safety of these agents. To this end, experience with DNMT inhibitors in hematologic malignancies other than MDS is reviewed in an effort to better understand the therapeutic potential of these agents and to define areas of future exploration in these settings.","PeriodicalId":51270,"journal":{"name":"Nature Clinical Practice. Oncology","volume":"2 Suppl 1 ","pages":"S36-44"},"PeriodicalIF":0.0,"publicationDate":"2005-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/ncponc0351","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25733148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 74

Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection. 甲基化抑制剂在骨髓增生异常综合征中的优化治疗:剂量、持续时间和患者选择。

Nature Clinical Practice. Oncology Pub Date : 2005-12-01 DOI: 10.1038/ncponc0355

Jean-Pierre Issa

引用次数: 85

DNA methylation and gene silencing in cancer. 癌症中的DNA甲基化和基因沉默。

Nature Clinical Practice. Oncology Pub Date : 2005-12-01 DOI: 10.1038/ncponc0354

Stephen B Baylin

引用次数: 1140

Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. 甲基化抑制剂治疗骨髓增生异常综合征。

Nature Clinical Practice. Oncology Pub Date : 2005-12-01 DOI: 10.1038/ncponc0347

Lewis R Silverman, Ghulam J Mufti

{"title":"Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.","authors":"Lewis R Silverman, Ghulam J Mufti","doi":"10.1038/ncponc0347","DOIUrl":"https://doi.org/10.1038/ncponc0347","url":null,"abstract":"The class of DNA methyltransferase inhibitors is represented by azacitidine and decitabine. Azacitidine is approved for the treatment of patients in both low- and high-risk subtypes of myelodysplastic syndrome (MDS), and decitabine is currently under review by the FDA. Azacitidine phase III trial data, based upon the Cancer and Leukemia Group B (CALGB) study 9221, showed durable clinical and symptomatic improvement in bone marrow function, a reduction in the risk of leukemic transformation, and significant improvements in the quality of life of patients treated with azacitidine compared with supportive care alone. This study also provided data suggestive of improvement in survival in MDS patients. The experience with decitabine comprises a number of phase I/II studies and a phase III trial yet to be published. While there is a strong base of experience supporting the efficacy of DNA methyltransferase inhibitors in the treatment of MDS, a number of practical issues need to be explored further. These include the optimization of the timing and duration of treatment, and the prediction of response to therapy. Along with current experience, future studies will lead to the development of treatment algorithms, strategies for selecting patients (e.g. according to age, risk, classification, and cytogenetic profile), and the combination strategies, particularly with histone deacetylase inhibitors, in the management of MDS.","PeriodicalId":51270,"journal":{"name":"Nature Clinical Practice. Oncology","volume":"2 Suppl 1 ","pages":"S12-23"},"PeriodicalIF":0.0,"publicationDate":"2005-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/ncponc0347","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25733750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 68

Myelodysplastic syndromes (MDSs) and acute myelogenous leukemia (AML) comprise a closely linked continuum of malignant hematologic diseases. Introduction. 骨髓增生异常综合征(mds)和急性髓性白血病(AML)构成了一个密切相关的恶性血液疾病的连续体。介绍。

Nature Clinical Practice. Oncology Pub Date : 2005-12-01 DOI: 10.1038/ncponc0352

Stephen B Baylin, Ghulam J Mufti

引用次数: 4